Loading chat...
DE HB233
Bill
Status
6/18/2019
Primary Sponsor
Debra Heffernan
Click for details
AI Summary
-
Expands the definition of "prescription drug order" to include written, verbal, and electronic prescriptions under Title 16 of the Delaware Code.
-
Adds Gabapentin to Schedule V of controlled substances, making it subject to state prescription monitoring and regulation.
-
Authorizes state oversight of Gabapentin prescribing due to increasing abuse, as the drug potentiates opioid effects and poses overdose risks when combined with opioids.
-
Aligns Delaware law with Kentucky, Ohio, and West Virginia, which have already classified Gabapentin as a Schedule V controlled substance.
Legislative Description
An Act To Amend Title 16 Of The Delaware Code Relating To The Uniform Controlled Substances Act.
Last Action
Reported Out of Committee (Health & Human Development) in House with 7 On Its Merits
6/19/2019